Author

Abdullah Khasawneh

Juntendo UniversityORCID 0000-0002-8324-4048Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Yoko TabeiD· 2 shared A. A. SherifiD· 1 shared Aditi ShastriiD· 1 shared Amit K. VermaiD· 1 shared Anna SkwarskaiD· 1 shared B. W. Brown· 1 shared Bianca Rivera-PeñaiD· 1 shared Chikako OnoiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Yoko TabeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia

Samarpana Chakraborty, Claudia Morganti, Kimberly S. Zaldana, Bianca Rivera-Peña, H. Zhang, Divij Verma, Nadege Gitego, Feiyang Ma, Srinivas Aluri, Kith Pradhan, Shanisha Gordon-Mitchell, Ioannis Mantzaris, Mendel Goldfinger, Eric Jay Feldman, Kira Gritsman, , Aditi Shastri

This paper shows that targeting STAT3 with a degrader can overcome Venetoclax resistance in AML by reducing MCL1 and improving mitochondrial function.

Leukemia · Feb 17, 2026Peer-reviewedCancer Biology

BCR, not TCR, repertoire diversity is associated with favorable COVID-19 prognosis

Faith Jessica Paran, Rieko Oyama, Abdullah Khasawneh, Tomohiko Ai, Hendra Saputra Ismanto, A. A. Sherif, Dianita S. Saputri, Chikako Ono, Mizue Saita, Satomi Takei, Yuki Horiuchi, Ken Yagi, Yoshiharu Matsuura, Yasushi Okazaki, Kazuhisa Takahashi, , Toshio Naito

This study finds that BCR repertoire diversity, not TCR diversity, correlates with favorable outcomes in COVID-19 patients.

Frontiers in Immunology · Oct 28, 2024Peer-reviewedImmunology